a-link-name=”in body link”>Last year, AstraZeneca announced a £90m state support offer from the previous government for a research and manufacturing centre in the Liverpool suburb of Speke. However, the company cancelled the project just hours after UK chancellor Rachel Reeves singled out the drugmaker as a “great companies” in her speech on UK growth. Keith Neal, emeritus professor of… Continue reading AstraZeneca, Whitehall, and a failed £450m deal for the next generation in vaccines. What went wrong?
Author: Julia Kollewe
From the Beatles to biologics – how Liverpool became a life science hotspot
innovative manufacturing sector. We are actively engaging with AstraZeneca to understand the reasons for their decision and what we can do to support them in their plans for the Speke site. Our record investment in science, research and development will deliver a pipeline of world-class technologies that will drive economic growth across the UK.” The… Continue reading From the Beatles to biologics – how Liverpool became a life science hotspot
AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project
After cancelling its £450m ($588m) vaccine expansion project at Liverpool’s Speke facility last week, AstraZeneca’s CEO, Pascal Soriot, has voiced his disappointment. Speaking to reporters, he said the drug maker’s investment required a higher level of economic support than the government felt was feasible. This had been previously agreed under a Conservative government which had… Continue reading AstraZeneca ‘very disappointed’ over axed £450m Liverpool vaccine project